All eyes on Novo's new outlook on eve of 2021 report

On Wednesday morning, when Novo Nordisk presents its full-year financial results prior to the stock exchange opening, the attention of analysts and investors will be on the outlook for the new year, as growth isn’t expected to match 2021 levels due to production issues with obesity drug Wegovy.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde
by marketwire, translated by daniel pedersen

All eyes will be fixed on Novo Nordisk’s 2022 guidance when the company publicizes its full-year report on Wednesday morning.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading